# Aegle Therapeutics

is running a Phase 1/2a trial of AGLE-102, an MSC-derived extracellular-vesicle therapy for dystrophic epidermolysis bullosa, having dosed its first patient and reported positive initial safety data.

Source: https://en.bioecon.ru/companies/aegle-therapeutics/
Updated: 2026-07-04

- Country: United States

## Technologies

- [Exosome therapy & extracellular vesicles](https://en.bioecon.ru/technology/exosome-therapy-extracellular-vesicles/)